Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Wockhardt Q1 net loss...

    Wockhardt Q1 net loss narrows to Rs 86 crore

    Written by Ruby Khatun Khatun Published On 2018-08-06T10:30:55+05:30  |  Updated On 6 Aug 2018 10:30 AM IST
    Wockhardt Q1 net loss narrows to Rs 86 crore

    New Delhi: Pharmaceutical firm Wockhardt reported narrowing of its consolidated net loss to Rs 86 crore for the quarter ended June.


    The company had registered a loss of Rs 410 crore in the same period a year ago.

    Consolidated revenue from sales increased by 13.13 percent to Rs 1,008 crore during the reported quarter from Rs 891 crore in the corresponding period of 2017-18.

    "The business performance of the company during the quarter ended June 30, 2018, showed marked improvement with sales growth of 13 percent as compared with the similar quarter of the previous year driven by growth in US, lndia business and growing emerging markets," the company said in a statement.

    India, US and Irish business of the company grew by 30 percent, 20 percent, and 7 percent respectively, while there was de-growth of 7 percent in the UK business.

    Research and development expenditure during the quarter was at Rs 61 crore (6 percent of sales) and including capital expenditure, it is at 8.3 percent of sales.

    "Capital expenditure during the quarter was Rs 73 crore," the statement said.
    capital expenditureFinancial resultsnarrowsnet lossQ1research and developmentrevenueWockhardt
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok